Proteasome inhibitor

Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma

Retrieved on: 
Thursday, October 1, 2020
Drugs, Orphan drugs, Health, RTT, Breakthrough therapy, Antineoplastic drugs, Multiple myeloma, Pyrazines, Proteasome inhibitor, Melflufen, Daratumumab, Selinexor

Melflufen (INN melphalan flufenamide), is currently being evaluated in several clinical studies as a treatment for patients with triple-class refractory multiple myeloma.

Key Points: 
  • Melflufen (INN melphalan flufenamide), is currently being evaluated in several clinical studies as a treatment for patients with triple-class refractory multiple myeloma.
  • The sEAPort program is available to adults, age 18 and older, who have received at least two prior lines of therapy and whose multiple myeloma is refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients).
  • The Expanded Access Program was initiated following the Company's June 30 submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for the treatment of adult patients with triple-class refractory multiple myeloma.
  • "Despite therapeutic advances, multiple myeloma remains incurable," said Paula O'Connor, U.S. Head of Medical Affairs at Oncopeptides.

Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients

Retrieved on: 
Wednesday, September 9, 2020
Cancer treatments, Drugs, Orphan drugs, RTT, Clinical medicine, Multiple myeloma, Proteasome inhibitor, Antineoplastic drugs, Pyrazines, Antibody-drug conjugates, B-cell maturation antigen, Selinexor

Triple class refractory is defined as patients refractory to immunomodulatory, proteasome inhibitors and anti-CD38 antibody drug classes.

Key Points: 
  • Triple class refractory is defined as patients refractory to immunomodulatory, proteasome inhibitors and anti-CD38 antibody drug classes.
  • The 40% ORR (6/15 patients) represents triple class refractory patients enrolled in Part A of Cellectars CLOVER-1 study and additional patients enrolled in Part B from March through May 2020.
  • We remain encouraged by the consistency of CLR 131s efficacy and tolerability data in these extremely challenging to treat triple class refractory multiple myeloma patients, said Dr. John Friend, CMO of Cellectar Biosciences.
  • The Phase 2 CLOVER-1 study is an open-label study designed to determine the efficacy and safety of CLR 131 in select B-cell malignancies.

Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy

Retrieved on: 
Friday, June 12, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Health, Takeda Pharmaceutical Company, Orphan drugs, Boronic acids, Ixazomib, Proteins, Proteasome inhibitor, Multiple myeloma, Proteasome, Therapy, Oncology, the TOURMALINE-MM4 Trial, the US MM-6 Trial, Multiple Myeloma, NINLARO, Takeda Pharmaceutical Company Limited

Data from this Phase 3 clinical trial reinforce the role of proteasome inhibition as a maintenance therapy and suggest that longer duration of therapy can improve a response, in addition to extending it.

Key Points: 
  • Data from this Phase 3 clinical trial reinforce the role of proteasome inhibition as a maintenance therapy and suggest that longer duration of therapy can improve a response, in addition to extending it.
  • The safety profile of NINLARO is consistent with previously reported results of single-agent NINLARO use and there were no new safety signals identified.
  • The positive data from the Phase 3 trial evaluating NINLARO as a maintenance therapy in patients not eligible for stem cell transplantation showed significant improvement in progression-free survival, said Christopher Arendt, Head, Oncology Therapeutic Area Unit, Takeda.
  • NINLARO (ixazomib) is an oral proteasome inhibitor which is being studied across the continuum of multiple myeloma treatment settings.

Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

Retrieved on: 
Thursday, January 9, 2020
Branches of biology, Oncolytics Biotech, Virotherapy, Reoviruses, Pelareorep, Proteasome inhibitor, Multiple myeloma, Proteasome, Oncolytic virus

SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at 10:30 am ET for their institutional clients.

Key Points: 
  • SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at 10:30 am ET for their institutional clients.
  • The call, "Proteasome Inhibitors Augment Pelareorep in Multiple Myeloma" will feature Dr. Flavia Pichiorri Ph.D. and Dr. Craig Hofmeister M.D., both of whom are working on ongoing multiple myeloma studies with Oncolytics' oncolytic virus, pelareorep.
  • Management plans to provide a recap of the call next week, including key messages and insights provided by Dr. Pichiorri and Dr. Hofmeister.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

Retrieved on: 
Thursday, January 9, 2020
Branches of biology, Oncolytics Biotech, Virotherapy, Reoviruses, Pelareorep, Proteasome inhibitor, Multiple myeloma, Proteasome, Oncolytic virus

SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ --Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at 10:30 am ET for their institutional clients.

Key Points: 
  • SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ --Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at 10:30 am ET for their institutional clients.
  • The call, "Proteasome Inhibitors Augment Pelareorep in Multiple Myeloma" will feature Dr. Flavia Pichiorri Ph.D. and Dr. Craig Hofmeister M.D., both of whom are working on ongoing multiple myeloma studies with Oncolytics' oncolytic virus, pelareorep.
  • Management plans to provide a recap of the call next week, including key messages and insights provided by Dr. Pichiorri and Dr. Hofmeister.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Fully-human BCMA CAR-T Clinical Results for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASH Annual Meeting

Retrieved on: 
Wednesday, December 11, 2019
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Branches of biology, Medical specialties, Multiple myeloma, RTT, Stem cells, Proteasome inhibitor, Bone marrow, Bortezomib, Relapsed/Refractory Multiple Myeloma, CT103A, IASO Bio, Innovent

In addition, 4 patients participating in the study had relapsed from a prior murine CAR-T infusion.

Key Points: 
  • In addition, 4 patients participating in the study had relapsed from a prior murine CAR-T infusion.
  • Multiple Myeloma is a deadly blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems and bone fractures.
  • For newly treated patients with multiple myeloma, common first-line treatment drugs include proteasome inhibitors, immunoregulatory drugs and alkane agents.
  • Founded in March 2017, IASO BIO is a clinical stage biotechnology company advancing the development of innovative cell therapies for cancer.

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting

Retrieved on: 
Tuesday, December 10, 2019
Medicine, Medical specialties, Organ systems, Multiple myeloma, RTT, Proteasome inhibitor, Bone marrow, Lenalidomide, Plasma cell dyscrasias

The oral presentation title is "Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma".

Key Points: 
  • The oral presentation title is "Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma".
  • Multiple Myeloma is a deadly blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems and bone fractures.
  • For newly treated patients with multiple myeloma, common first-line treatment drugs include proteasome inhibitors, immunoregulatory drugs and alkane agents.
  • IASO BIO is developing over 10 high-potential, high-end biopharmaceutical products, targeting hematological and solid tumors.

Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Friday, September 13, 2019
Drugs, Clinical medicine, Medicine, Orphan drugs, Monoclonal antibodies, RTT, Breakthrough therapy, Daratumumab, Carfilzomib, Multiple myeloma, Proteasome inhibitor, Genmab

In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

Key Points: 
  • In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.
  • The Phase III trial (NCT03158688) is a randomized, open-label study that includes approximately 460 patients with multiple myeloma who have relapsed after 1 to 3 prior therapies.
  • Patients were randomized to receive either daratumumab in combination with carfilzomib (a proteasome inhibitor) and dexamethasone (a corticosteroid) or carfilzomib and dexamethasone alone.
  • A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings.

Spherix is Granted Exclusive Option to License Anticancer Drug from the University of Kentucky

Retrieved on: 
Wednesday, September 11, 2019
Proteasome inhibitor, Spex

NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor.

Key Points: 
  • NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor.
  • Under the Option, Spherix has until late November to complete its due diligence and execute a license agreement for commercial development.
  • "Early research indicates great potential for the University of Kentucky's anticancer drug G4-1.
  • The published data is extremely encouraging, especially the drug's benefits over already-approved drugs," stated Mr. Anthony Hayes, CEO of Spherix.

Proteasome Inhibitors Market Size Worth $1.7 Billion by 2023 - Technavio

Retrieved on: 
Tuesday, July 9, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Chemistry, Branches of biology, Physical sciences, Proteasome inhibitor, Takeda Pharmaceutical Company, Proteasome, Bortezomib, Carfilzomib, Boron

The global proteasome inhibitors market size is poised to reach USD 1.7 billion by 2023, according to a new report by Technavio, progressing at a CAGR of close to 8% during the forecast period.

Key Points: 
  • The global proteasome inhibitors market size is poised to reach USD 1.7 billion by 2023, according to a new report by Technavio, progressing at a CAGR of close to 8% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20190709005040/en/
    Technavio has published a new market research report on the global proteasome inhibitors market from 2019-2023.
  • Read a 136-page research report with TOC on "Proteasome inhibitors Market Analysis Report by product (VELCADE, KYPROLIS, NINLARO, and other products), and segment forecasts for 2019 to 2023" at
    The market has only a limited number of approved therapies for multiple myeloma, with three branded proteasome inhibitors and one generic proteasome inhibitors approved.
  • Tyrosine Kinase Inhibitors Market Global tyrosine kinase inhibitors Market report provides a detailed analysis of the market by product (RTKIs and nRTKIs) and geography (the Americas, APAC, and EMEA).